

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
2 October 2003 (02.10.2003)

PCT

(10) International Publication Number  
**WO 03/079989 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K**
- (21) International Application Number: PCT/US03/08503
- (22) International Filing Date: 20 March 2003 (20.03.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
10/103,234 21 March 2002 (21.03.2002) US
- (71) Applicant: **CERAMOPTEC INDUSTRIES, INC.**  
[US/US]; 515 Shaker Road, East Longmeadow, MA 01028 (US).
- (72) Inventor: **NEUBERGER, Wolfgang**; 905 Beta Tower Financial Park, 87000 F.T. Labuan (MY).


- (74) Common Representative: **SKUTNIK, Bolesh, J.**; CeramOptec Industries, Inc., 515 Shaker Road, East Longmeadow, MA 01028 (US).
- (81) Designated States (*national*): AU, BR, CA, CN, JP, KR.
- (84) Designated States (*regional*): European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

**Published:**

- without international search report and to be republished upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: DEVICE AND METHOD FOR MINIMIZING RESTENOSIS AFTER ANGIOPLASTY TREATMENT



(57) Abstract: A novel device and method for preventing restenosis and streamlining the angioplasty procedure. The device and method provide a fiberoptic guidewire, or, alternatively, a light-conducting catheter, to decrease the size of the angioplasty device, decrease the overall time of the procedure, and increase the safety of the procedure. The present invention delivers radiation to a sclerotized area after balloon angioplasty treatment to prevent restenosis. Radiation delivered via the catheter or fiberoptic guidewire discourages the cell proliferation and cell growth after angioplasty, thereby improving the chances of avoiding restenosis.

WO 03/079989 A2

## Device and Method for Minimizing Restenosis After Angioplasty Treatment

### Background of the Invention

#### 1. Field of the invention

This invention relates generally to a method and device using a targeted light source and a photosensitizer to streamline the process of repairing internal body passageways, prevent restenosis, and minimize re-injury after angioplasty treatment.

#### 2. Invention Disclosure Statement

The most common problem with any angioplasty procedure is restenosis, a re-closing of the affected passageway opened by the procedure. This effect is believed to be due to cell proliferation, triggered by the exerted pressure and the lesion caused by the balloon angioplasty. Restenosis occurs in about 30% of patients. The use of stents, or tiny expanding metal scaffolds, is the most common method used to prevent restenosis. However, restenosis through the stent or around the stented area is quite common.

Constrictions in the coronary artery are caused by a buildup of plaque. Plaque can occur in many forms, from a thick viscous consistency (similar to toothpaste) to a rock-hard consistency depending on the proportion of components, which may include calcium, fibrous tissue, fatty deposits, organized clots and thrombus.

Atherosclerosis is a common problem among humans. Fatty substances (lipids), or plaques, form deposits in and beneath the intima—the innermost membrane lining arteries and veins. Atherosclerosis commonly affects large and medium sized arteries. Most commonly affected are the aorta, and the iliac, femoral, coronary, and cerebral arteries. Health problems result from atherosclerosis when reduced blood flow due to constriction of one of the passageways restricts blood flow to a particular tissue or organ. Restricted blood flow compromises and restricts organ or tissue function.

Approximately four million people in the United States suffer from arteriosclerotic coronary artery disease. Many of these people are likely to suffer or die from myocardial infarction, commonly known as heart attack. Heart disease is, in

fact, the leading cause of death in the United States. Thrombosis in the coronary artery beyond the arteriosclerotic constriction is the usual cause of heart attacks. A procedure that can open arteriosclerotic constrictions thereby permitting the normal flow of blood to the heart can reduce many deaths and disabilities caused by heart disease.

Modern treatment of atherosclerotic blood passageways usually involves one of two treatments: bypass and/or angioplasty. In bypass treatment, a portion of a blood passageway is borrowed from another area in the body and grafted around the affected passageway. This treatment involves invasive surgery, especially when dealing with the aorta, coronary artery, or other vessels involving the heart. Furthermore, bypass surgery does not heal the affected site, and occurrences of atherosclerosis in the grafted passage are relatively common.

Another method of treating atherosclerosis is angioplasty. In angioplasty, a catheter of some sort is introduced into the passageway. In most methods, the angioplasty catheter, usually equipped with a guidewire, moves along the body passageway to the sclerotized area. A balloon contained inside of the catheter inflates, displacing the plaque and re-opening the passageway.

In another use of the prior art, a photosensitizer is introduced at the sclerotized area prior to introduction of the catheter. After time for the photosensitizer to target and saturate the sclerotized area, a catheter is introduced into the body passageway. Fibers are then inserted into the catheter. The fibers conduct light from some kind of source, i.e. a laser. The laser or other light source activates the photosensitizer in the sclerotized area in order to destroy the plaque. A balloon may or may not be used in this approach to further treat the sclerotized area of the blood passageway. This form of angioplasty is called Photodynamic Therapy (PDT), or intracoronary brachytherapy.

The photoactivating device employed for intracoronary brachytherapy usually comprises a monochromatic light source such as a laser, the light output of which may be coupled to an invasive light delivery catheter for conduction and delivery to a remote target tissue. Such interventional light delivery catheters are well known in the art and are described, for example, in US Patent 4,512,762 (Spears). In that invention a balloon is illuminated to activate the photosensitizer.

Generally, the prior art of intracoronary brachytherapy involves at least five steps: insertion of a guidewire; insertion of a catheter over the guidewire; removal of the guidewire; insertion of a fiberoptic wire; and finally, irradiation. The present invention is a method to prevent restenosis by using a novel catheter with light  
5 conducting means and a targeting mechanism for focusing that light source on a photosensitizer to treat a sclerotized area of a human body passageway. Most balloon angioplasty procedures do not involve radiation to prevent cell growth in the intima. Instead, they aim to compress or displace cells in a sclerotized vessel with a stent or other means. These treatments tend to encourage restenosis by stimulating a  
10 responsive force in the vessel wall, or stimulating the proliferation of cells in the area to re-take its original shape.

The present invention provides a non-mechanical method and product for preventing restenosis by irradiation. A "fiberoptic guidewire" assists the doctor or technician in navigating body passageways, and also conducts radiation to its own  
15 diffuser to engage in PDT. Alternatively, a balloon catheter is manufactured to conduct radiation to an obstructed body passageway. Either embodiment streamlines the angioplasty procedure.

### **Objectives and Brief Summary of the Invention**

20 It is an object of the present invention to provide a method to prevent or minimize occurrences of restenosis after angioplasty.

It is also an object of the present invention to streamline the process of angioplasty to reduce patient exposure and increase the safety of the process.

25 It is another object of the present invention to provide a guidewire capable of transmitting radiation, hereinafter referred to as a "fiberoptic guidewire," to streamline the angioplasty process and prevent restenosis.

It is a further object of the present invention to provide a fiberoptic guidewire with a diffuser end capable of transmitting radiation to a sclerotized body  
passageway.

30 It is still another object of the present invention to provide a catheter manufactured to conduct radiation, either by insertion of optical fibers in the tubular

structure or by manufacturing the catheter of a homogeneous light-conducting polymer.

Briefly stated, the present invention provides a novel device and method for preventing restenosis and streamlining the angioplasty procedure. The device and method provide a fiberoptic guidewire, or, alternatively, a light-conducting catheter, to decrease the size of the angioplasty device, decrease the overall time of the process, and increase the safety of the procedure. The present invention delivers radiation to a sclerotized area after balloon angioplasty treatment to prevent restenosis. Radiation delivered via the catheter or fiberoptic guidewire discourages the cell proliferation and cell growth after angioplasty, thereby improving the chances of avoiding restenosis.

The above, and other objects, features and advantages of the present invention will become apparent from the following description read in conjunction with the accompanying drawings.

#### Brief Description of Figures

Fig. 1 shows a fiberoptic guidewire with a diffuser in a sclerotized body passageway.

Fig. 2 is a continuation of Fig 1, showing a balloon catheter circumscribing the fiberoptic guidewire in the sclerotized body passageway.

Fig. 3 shows a balloon catheter equipped with optical fibers in its tubular structure circumscribing a conventional guidewire.

Fig. 4 is a cross section of the catheter described in Fig. 3 down its longitudinal axis.

Fig. 5 is another embodiment of the catheter in Fig 3 manufactured of a light-conducting polymer.

#### Detailed Description of Preferred Embodiments

The entire angioplasty process is streamlined considerably by the present invention. In the present state of the art, there are several steps to the angioplasty procedure: Introduction of a standard guidewire; introduction of a catheter over a guidewire; removal of the guidewire; introduction of an optical fiber; inflation of the

balloon, irradiation, and removal of the entire system. In the present invention, light radiation is transmitted through the fiberoptic guidewire, or alternatively the catheter. The length and complication of the angioplasty process is greatly decreased. A fiberoptic guidewire eliminates the need for of different means for navigation and irradiation. The prior art provides for separate fibers or possibly separate lumens in the catheter for movement over the guidewire and transmission of radiation. The present invention streamlines the process by combining the functions of the guidewire and radiation transmitter, or by transmitting radiation via the catheter itself. The manufacture of a catheter with light-conducting properties also alleviates the need for removal of the guidewire and insertion of a means of irradiation. Decreasing the amount of time that a vessel is subject to a foreign body increases the safety of the process. In addition, the size of the device decreases with the decreased need for lumens for a guidewire, gas, and fiberoptic transmission.

In one preferred embodiment, a fiberoptic guidewire is manufactured in accordance with Figure 1. This fiberoptic guidewire alleviates the need for a separate fiber or wire for irradiation.

A photosensitizer is introduced at a sufficient time prior to beginning the minimally invasive procedure to allow for, preferably, location and targeting of the sclerosis and/or plaque. The fiberoptic guidewire is then introduced into the body passageway. The fiberoptic guidewire has a diffuser located near the distal end. The diffuser will allow for homogeneous and/or differential distribution of radiation at a selected power and intensity to discourage growth and proliferation of the cells in either the vessel walls or the plaque. Various methods of creating homogeneous diffusion are known in the prior art. US Patent 5,196,005 (Doiron & Narcise) describes a method for placing diffusion tips on optical fibers. US Patent 5,231,684 (same inventors) describes the use of a microlens attached to the end of an optical fiber for diffusion of radiation. The present invention envisions a diffuser with a section of guidewire extending distally for optimal navigation in a body passageway. A variation of the prior art that allows an extension of guidewire distally from the distal end of the diffuser is used in the present invention.

Extending distally from the diffuser, a short piece of guidewire allows for conventional navigational advantages of a guidewire for location of the affected area

of the body passageway. The proximal end of the fiberoptic guidewire extends from the diffuser through the body passageway to the portion exiting from the patient and connected to the light source. Methods and devices to allow handling and movement of the guidewire by a doctor or technician are known in the prior art.

5 By using the described fiberoptic guidewire, the means to transmit radiation are in place. A balloon catheter is then introduced that circumscribes the guidewire, as shown in Figure 2. After proper positioning of the catheter, the balloon is inflated to displace the plaque. The light source connected to the proximal end of the guidewire is then activated, irradiating the plaque and vessel walls. Irradiating the  
10 plaque and activating the photosensitizer located within the plaque discourages cell proliferation and growth—two responses by the cell wall and/or plaque buildup to an exerted force (the angioplasty balloon) that cause restenosis in 30% of patients that receive angioplasty treatment.

15 In another preferred embodiment, the light conducting means are located within the catheter. In this device, a photosensitizer is again introduced. A standard, non-fiberoptic guidewire is introduced to assist the doctor or technician in navigating the body passageway to the sclerosis or constriction. The balloon catheter, again circumscribing the guidewire, is introduced and navigated along the guidewire to the affected area.

20 The catheter is manufactured to conduct radiation to the affected area. In one variation of the present embodiment, the tubular structure of the balloon catheter is manufactured in accordance with Figure 4. Optical fibers embedded in the tubular structure are enclosed in lumens that allow space for differential bending and extension/contraction of the fibers as opposed to the catheter body itself. Fibers of  
25 quartz, glass, and plastic are known in the field of fiberoptics and are suitable for use in this embodiment. At least one other lumen exists for free movement of the guidewire relative to the catheter.

30 The larger lumens for optical fibers can also be used for transmission of a gas or liquid for inflation of the balloon. The use of gases or liquids for inflation of a balloon catheter is well known in the art. US Patent 4,512,762 (Spears) describes the use of a lumen to transmit pressurized gas to a balloon catheter for inflation. The optical fibers extend distally to the balloon itself, where they transmit radiation to the

balloon. Upon inflation of the balloon and displacement of the plaque, the light source is activated, transmitting radiation along the optical fibers and to the inflated balloon. The means of transmission is designed for homogeneous or, if desired, differential transmission of radiation throughout the balloon to the sclerotized area for maximum irradiation.

The irradiation of the plaque and vessel walls activates the photosensitizer and prevents restenosis by discouraging cell growth and cell proliferation in the vessel walls and the plaque. These processes of growth and proliferation are generally attributed as causes of restenosis.

In another variation of this preferred embodiment, the catheter body itself is manufactured using a homogeneous light-conducting polymer in accordance with Figure 5. This polymer will conduct radiation from a light source on its proximal end to the affected area through the angioplasty balloon. At the distal end of the catheter, a diffuser section of the catheter transmits radiation from the catheter walls to the balloon or directly to the plaque and vessel wall. There are several diffusers that are well known in the field of PDT that can be used, or variations of those diffusers can be manufactured to ideally suit the present application.

The catheter contains at least one lumen for circumscribing the guidewire and transmission of a liquid or gas for inflation of the catheter balloon. In this variation, the angioplasty procedure would be similar to the previous variation. The photosensitizer is introduced; a guidewire is inserted. The catheter is inserted over the guidewire, and the balloon is inflated, displacing the obstruction in the body passageway. The area is then irradiated, preventing restenosis.

Once again, the angioplasty procedure is streamlined by introduction of a catheter with light-conducting properties designed specifically for transmission of radiation to an obstruction in a human blood vessel or other body passageway eliminates the need for a separate fiber introduced solely for the purpose of transmitting radiation. The time saved in the procedure translates into increased safety for the patient undergoing angioplasty treatment.

The present invention is further illustrated by the following examples, but is not limited thereby.



*Example 1:* Figure 1 shows body passageway 100 affected with obstruction 102. The distal end 106 of guidewire 104 extends beyond diffuser 108, which is positioned at obstruction 102. The guidewire 104 is constructed of a fiberoptic material, allowing for conduction of radiation during the angioplasty process. As shown in Figure 2, balloon catheter 206 is inserted into body passageway 200, circumscribing the guidewire 204 up to the end of the diffuser 210. When the catheter 206 is properly positioned, balloon 208 is inflated, displacing plaque or other obstruction 202. After displacement, a light source connected to the proximal end of guidewire 204 is activated, transmitting radiation to diffuser 210 and through balloon 208. The irradiation stops the re-growth and proliferation of plaque or other obstructions that cause restenosis.

*Example 2:* Figure 3 shows a conventional guidewire 302 circumscribed by a catheter in an affected body passageway 300. The guidewire 302 is inserted, the distal tip extending a distance beyond the affected area 304. The balloon catheter 306 is then introduced, circumscribing the guidewire 302. Optical fibers 308 are contained within the tubular structure of catheter 306. The angioplasty balloon is positioned at obstruction 304 and inflated. The balloon 310 displaces plaque 304. A light source connected to the proximal end of optical fibers 308 is activated, transmitting radiation to balloon 310. Irradiation of the plaque 304 prevents cell growth and regeneration, the causes of restenosis. Figure 4 shows a cross section, looking down the longitudinal axis, of catheter 400. Lumens 402 are circular or otherwise shaped for optimal sizing of the catheter structure 400. Optical fibers 404 are smaller than lumens 402 to allow for movement and prevent cracking or breaking of fibers 404. At least one lumen 406 exists in the catheter body 400 for circumscribing the guidewire 408 and for transmission of a gas or liquid for inflation of the angioplasty balloon.

*Example 3:* In a variation of Example 2 shown in Figure 5, catheter body 500 is manufactured as a light-conducting polymer. The catheter 500 contains at least one lumen 502 for transmission of gas or liquid to inflate the catheter and to circumscribe the guidewire 504. The processes of angioplasty and irradiation are similar to Example 2. Radiation is transferred through the light-conducting body of the catheter

500 to an angioplasty balloon in sufficiently homogeneous form to transfer to the angioplasty balloon when inflated, irradiating the obstruction in the body passageway. This homogeneous transmission can be accomplished by use of a simple diffuser. The diffuser transmits radiation from the polymer-based catheter body 500 to the  
5 balloon or directly to the obstructed area of the body passageway.

Having described preferred embodiments of the invention with reference to the accompanying drawings, it is to be understood that the invention is not limited to the precise embodiments, and that various changes and modifications may be effected  
10 therein by skilled in the art without departing from the scope or spirit of the invention as defined in the appended claims.

**What is claimed is:**

1. An improved angioplasty catheter system, which reduces occurrence of restenosis, wherein said improvement comprises:  
means for providing homogeneous radiation to a treatment site after or during dilation of an occluded section; and  
wherein said means is integrated into said angioplasty catheter system to provide said radiation more simply and seamlessly than current standards.
2. The improved angioplasty catheter according to claim 1, wherein said means for providing homogeneous radiation is a fiberoptic guidewire, which integrates guiding function with said means for providing homogeneous radiation, said fiberoptic guidewire comprising:  
an optical fiber having a proximal end and a distal end, whose proximal end is adapted to connect to an optical source; and  
wherein said distal end has a section of standard guidewire attached to a distal end of a diffusing section which is positioned at said optical fiber's distal end.
3. The improved angioplasty catheter according to claim 1, wherein said means for providing homogeneous radiation are optical fibers in channels within said catheter's wall, which integrates catheter structure with said means for providing homogeneous radiation, said catheter wall at a distal end being transparent to said homogeneous radiation, providing means to scatter said radiation outward from said optical fibers at said distal end of said catheter, and wherein at least one of said channels also function to inflate a balloon of said angioplasty catheter system.
4. The improved angioplasty catheter system of claim 1, wherein said means for providing homogeneous radiation is making said catheter's wall out of a material which transmits said radiation and providing a means for scattering outward said radiation at a distal end of said catheter.
5. A streamlined method of angioplasty to reduce occurrence of restenosis comprising the steps of:

introducing a photosensitizing moiety or its precursor into a patient and allowing it to enter said patient's blood vessels;

using a balloon catheter to dilate an occluded section of a vessel at a treatment site;

providing means to homogeneously irradiate said dilated section at said treatment site, wherein said means to homogeneously irradiate are integrated with said balloon catheter; and,

irradiating said treatment site to activate said photosensitizing moiety.

6. A streamlined method of angioplasty according to claim 8, wherein said integration of said means to homogeneously irradiate said treatment site with said catheter is selected from the group consisting of: a fiberoptic guidewire, optical fibers in channels within said catheter's wall, and making said catheter's wall out of a material which transmits said radiation.

FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4





FIGURE 5



(19) World Intellectual Property Organization  
International Bureau




(43) International Publication Date  
2 October 2003 (02.10.2003)

PCT

(10) International Publication Number  
**WO 03/079989 A3**

- (51) International Patent Classification<sup>7</sup>: **A61B 18/18** (74) Common Representative: **SKUTNIK, Bolesh, J.**, CeramOptec Industries, Inc., 515 Shaker Road, East Longmeadow, MA 01028 (US).
- (21) International Application Number: **PCT/US03/08503**
- (22) International Filing Date: **20 March 2003 (20.03.2003)** (81) Designated States (*national*): **AU, BR, CA, CN, JP, KR.**
- (25) Filing Language: **English** (84) Designated States (*regional*): **European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).**
- (26) Publication Language: **English**
- (30) Priority Data: **10/103,234** **21 March 2002 (21.03.2002)** **US** Published: **— with international search report**
- (71) Applicant: **CERAMOPTEC INDUSTRIES, INC.** [US/US]; 515 Shaker Road, East Longmeadow, MA 01028 (US). (88) Date of publication of the international search report: **18 December 2003**
- (72) Inventor: **NEUBERGER, Wolfgang**; 905 Beta Tower Financial Park, 87000 F.T. Labuan (MY). *For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **DEVICE AND METHOD FOR MINIMIZING RESTENOSIS AFTER ANGIOPLASTY TREATMENT**



(57) Abstract: A novel device and method for preventing restenosis and streamlining the angioplasty procedure. The device and method provide a fiberoptic guidewire (104, 204, 302), or, alternatively, a light-conducting catheter (500), to decrease the size of the angioplasty device, decrease the overall time of the procedure, and increase the safety of the procedure. The present invention delivers radiation to a sclerotized area after balloon angioplasty treatment to prevent restenosis. Radiation delivered via the catheter (500) or fiberoptic guidewire (104, 204, 302) discourages the cell proliferation and cell growth after angioplasty, thereby improving the chances of avoiding restenosis.

WO 03/079989 A3



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/08503

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
IPC(7) : A61B 18/18 US CL : 606/007,15; 607/88, 89 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols) U.S. : 606/007,15; 607/88,89; 604/20; 250/493.1		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,169,395 A (Narciso, Jr.) 8 December 1992. See Figs. 1, 5-7, and 14; Col. 1, lines 58-61; Col. 3, lines 31-33; and Col. 6, lines 18-35 and 50-58.	1
Y	US 5,607,419 A (Amplatz et al.) 4 March 1997. See Figs. 1 and 2; Col. 2, lines 39-43; Col. 3, lines 12-35; and Col. 3, line 52 to Col. 4, line 5.	1-6
Y	US 5,620,438 A (Amplatz et al.) 17 April 1997. See Fig. 1.	1-6
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
<b>* Special categories of cited documents:</b>		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"I"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed	
Date of the actual completion of the international search 25 August 2003 (25.08.2003)		Date of mailing of the international search report 01 OCT 2003
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703)305-3230		Authorized officer Ahmed M. Fagan Telephone No. (703)305-3590